134756-61-9

Upstream product

• 100021-11-2 (1α,2β,3α)-2-(benzyloxymethyl)cyclopent-4-ene-1,3-diol 
• 108-24-7 acetic anhydride 

Downstream Products

• 134756-62-0 <1(S)-(1α,4α,5β)>-4-(acetyloxy)-5-<(benzyloxy)methyl>-2-cyclopenten-1-ol 
• 144069-03-4 (+)-(1α,2β,3α)-1-acetoxy-2-<(phenylmethoxy)methyl>cyclopent-4-en-3-ol 
• 124583-63-7 ((1bS,4aS,5S)-5-Benzyloxymethyl-1b,4a,5,5a-tetrahydro-1aH-1,4-dioxa-2-aza-cyclopropa[a]pentalen-3-yl)-dimethyl-amine 
• 134756-64-2 <1(R)-(1α,4α,5β)>-5-<(benzyloxy)methyl>-4-<(tert-butyldimethylsilyl)oxy>-2-cyclopenten-1-ol carbamate 
• 174810-43-6 Acetic acid (1R,4S,5S)-5-benzyloxymethyl-4-(tert-butyl-dimethyl-silanyloxy)-cyclopent-2-enyl ester 
• 134756-63-1 <1(R)-(1α,4α,5β)>-5-<(benzyloxy)methyl>-4-<(tert-butyldimethylsilyl)oxy>-2-cyclopenten-1-ol 
• 134756-65-3 <1(R)-(1α,2β,3α)>-2-<(benzyloxy)methyl>-4-cyclopentene-1,3-diol monocarbamate 
• 134875-87-9 <3a(R)-(3aα,6α,6aα)>-6-<(benzyloxy)methyl>-3,6a-dihydro-N,N-dimethyl-6H-cyclopentoxazol-2-amine 
• 134875-85-7 <3a(R)-(3aα,6α,6aα)>-6-<(benzyloxy)methyl>-3,3a,6,6a-tetrahydro-2H-cyclopentoxazol-2-one 
• 143994-97-2 Acetic acid (1R,2R,3S,4S,5S)-3-benzyloxymethyl-4-(2-methoxy-ethoxymethoxy)-6-oxa-bicyclo[3.1.0]hex-2-yl ester 
• 100101-50-6 <1S-(1α,2β,3α,4α,5β)>-2-azido-3,4-(dimethylmethylenedioxy)-5-<(phenylmethoxy)methyl>-1-cyclopentanol 
• 184179-62-2 Carbamic acid (1S,4R,5R)-5-benzyloxymethyl-4-(tert-butyl-dimethyl-silanyloxy)-cyclopent-2-enyl ester 
• 184179-65-5 (3aS,4S,5S,6S,6aR)-6-Benzyloxymethyl-2-dimethylamino-4,5,6,6a-tetrahydro-3aH-cyclopentaoxazole-4,5-diol 
• 184179-67-7 ((1aR,1bR,4aR,5R,5aS)-5-Benzyloxymethyl-1b,4a,5,5a-tetrahydro-1aH-1,4-dioxa-2-aza-cyclopropa[a]pentalen-3-yl)-dimethyl-amine 

Relevant academic research and scientific papers

Preparation of a chiral synthon for an HBV inhibitor: Enzymatic asymmetric hydrolysis of (1α,2β,3α)-2-(benzyloxymethyl)cyclopent-4-ene-1, 3-diol diacetate and enzymatic asymmetric acetylation of (1α,2β, 3α)-2-(benzyloxymethyl)cyclopent-4-ene-1,3-diol

Enantioselective asymmetric hydrolysis of (1α,2β,3α)-2- (benzyloxymethyl)-cyclopent-4-ene-1,3-diol diacetate 1 to the corresponding (+)-monoacetate 2 was carried out using lipase PS-30 from Pseudomonas cepacia or pancreatin. A reaction yield of 85 M % wit

The total synthesis of allosamidin. Expansions of the methodology of azaglycosylation pursuant to the total synthesis of allosamidin. A surprising enantiotopic sense for a lipase-induced deacetylation

Allosamidin, recently isolated from mycelial extracts of Streptomyces sp. 1713, is a powerful and selective chitinase inhibitor. The total synthesis of allosamidin is described herein. The electric eel acetylcholinesterase-mediated enantioselective hydrolysis of (trans,trans)-2-(benzyloxy)cyclopentene-1,3-diol diacetate accessed a monoacetyl derivative. Five additional steps produced a protected version of the aglycon ('allosamizoline') sector of allosamidin. An allal derivative stereoselectively reacted with benzenesulfonamide in the presence of a halonium source to afford a 2β-halo-1α-sulfonamidohexose. Treatment of this product with a strong base generated an intermediate 1,2-sulfonylaziridine, which was trapped with a protected allal derivative to provide a disaccharide glycal. Reiteration of this scheme gave access to the required trisaccharide. Following deprotection, the total synthesis of allosamidin was accomplished. In addition, the method, with modification, gave access to several allosamidin analogs.